Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:22 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 284 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Relapse-Remitting Multiple Sclerosis Clear all

Conditions: Multiple Sclerosis
Interventions: ELND002, Placebo; Drug
Lead sponsor: Elan Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 17
States / cities: Berkeley, California • Fresno, California • Newport Beach, California + 14 more

Conditions: Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Interventions: Ocrelizumab; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Brief Education, Motivational Interviewing-Cognitive Behavioral Therapy; Behavioral
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 2
States / cities: Kansas City, Missouri • West Orange, New Jersey

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: BG00002 (natalizumab), interferon beta-1a, glatiramer acetate; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 19
States / cities: Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 16 more

Conditions: Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions: There is no intervention in this study; Other
Lead sponsor: ProgenaBiome; Other
Eligibility: 12 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2030
U.S. locations: 1
States / cities: Ventura, California

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: Acthar; Drug
Lead sponsor: OhioHealth; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Sclerosis
Interventions: mycophenolate mofetil (Cellcept), human interferon beta 1a (Rebif); Drug
Lead sponsor: Aaron Boster; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 36
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 2,199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 32
States / cities: Cullman, Alabama • Sun City, Arizona • Tucson, Arizona + 29 more

Conditions: Relapsing-remitting Multiple Sclerosis
Interventions: Evobrutinib, Avonex®, Avonex® matched Placebo, Evobrutinib matched Placebo; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Relapsing-Remitting Multiple Sclerosis
Interventions: Glatiramer Acetate, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 25
States / cities: Cullman, Alabama • Fresno, California • La Jolla, California + 17 more

Conditions: Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
Interventions: GEMS Plus, GEMS; Behavioral
Lead sponsor: Kessler Foundation; Other
Eligibility: 16 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
Interventions: estriol, Placebo, Norethindrone, Progestin Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Observation of Ocrelizumab as Treatment in RRMS Patients; Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Relapsing Remitting Multiple Sclerosis
Interventions: alemtuzumab GZ402673; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 52
States / cities: Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Relapsing Forms of Multiple Sclerosis
Interventions: EHP-101 25 mg OD, EHP-101 25 mg BID, EHP-101 50 mg OD, EHP-101 50 mg BID; Drug
Lead sponsor: Emerald Health Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Cullman, Alabama • Fullerton, California • Port Orange, Florida

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Rocky Mountain MS Research Group, LLC; Other
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Relapsing Multiple Sclerosis, Clinically Isolated Syndrome, Relapsing-remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Sclerosis
Interventions: Avonex® monotherapy (6.0 MIU administered i.m. each week); Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Sclerosis
Interventions: Laquinimod, Placebo, Avonex®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 31 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Multiple Sclerosis
Interventions: MSDx Complex-1 Biomarker Test; Other
Lead sponsor: MSDx, Inc.; Industry
Eligibility: 45 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Relapse Remitting Multiple Sclerosis
Interventions: Blood Draw; Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis
Interventions: Betaseron, Copaxone; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 18 Years to 55 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Newark, New Jersey

Search by objective public record fields.

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

Combination Therapy Using Cellcept and Rebif in RRMS

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Study of Evobrutinib in Participants With RMS

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409

Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis

Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk

Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies

Effect of Interferon Beta-1a (Avonex®) on Changes of Non-conventional MRI Measures in Patients With MS

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients

A Cross-Sectional Study of MSDx Complex 1 as a Marker for Active Disease in Multiple Sclerosis

Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI